Allianz Group highlights global presence and financial results for 2024

Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) Allianz SE
Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) - Allianz SE
0Comments

The Allianz Group, a major insurer and asset manager, operates in nearly 70 countries and serves both private and corporate clients. The company offers a wide range of insurance products, including property, life, health, assistance services, credit insurance, and global business coverage.

Allianz manages approximately 768 billion euros in assets for its insurance customers as of March 31, 2025. In addition to these holdings, its asset management subsidiaries PIMCO and Allianz Global Investors oversee about 1.9 trillion euros in third-party assets. The company has incorporated ecological and social considerations into its business processes and investment decisions. This approach has helped Allianz become recognized as an industry leader in the Dow Jones Sustainability Index.

In 2024, Allianz employed more than 156,000 people worldwide. That year, the group reported a total business volume of 179.8 billion euros and an operating profit of 16.0 billion euros.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.